La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Youcare Pharmaceutical Group Résultats passés
Passé contrôle des critères 1/6
Youcare Pharmaceutical Group's earnings have been declining at an average annual rate of -13.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 4.9% per year. Youcare Pharmaceutical Group's return on equity is 4.7%, and it has net margins of 4.2%.
Informations clés
-13.4%
Taux de croissance des bénéfices
-19.0%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 10.9% |
| Taux de croissance des recettes | -4.9% |
| Rendement des fonds propres | 4.7% |
| Marge nette | 4.2% |
| Prochaine mise à jour des résultats | 23 Aug 2024 |
Mises à jour récentes des performances passées
Recent updates
Youcare Pharmaceutical Group Co., Ltd.'s (SHSE:688658) Price Is Out Of Tune With Earnings
Aug 16
Youcare Pharmaceutical Group Co., Ltd. (SHSE:688658) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Apr 21There's Reason For Concern Over Youcare Pharmaceutical Group Co., Ltd.'s (SHSE:688658) Massive 26% Price Jump
Mar 04Ventilation des recettes et des dépenses
Comment Youcare Pharmaceutical Group gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 24 | 4,036 | 169 | 1,819 | 364 |
| 31 Dec 23 | 4,196 | 185 | 1,969 | 352 |
| 30 Sep 23 | 3,998 | 152 | 1,891 | 314 |
| 30 Jun 23 | 4,813 | 402 | 2,290 | 318 |
| 31 Mar 23 | 4,770 | 357 | 2,288 | 344 |
| 31 Dec 22 | 4,542 | 335 | 2,234 | 344 |
| 30 Sep 22 | 5,123 | 507 | 2,617 | 363 |
| 30 Jun 22 | 4,763 | 473 | 2,438 | 305 |
| 31 Mar 22 | 4,987 | 539 | 2,582 | 241 |
| 31 Dec 21 | 4,966 | 545 | 2,572 | 200 |
| 30 Sep 21 | 4,879 | 562 | 2,538 | 146 |
| 30 Jun 21 | 4,789 | 523 | 2,506 | 136 |
| 31 Mar 21 | 4,481 | 476 | 2,299 | 137 |
| 31 Dec 20 | 4,339 | 442 | 2,176 | 128 |
| 30 Sep 20 | 4,096 | 358 | 2,058 | 116 |
| 31 Dec 19 | 4,288 | 285 | 2,052 | 126 |
| 31 Dec 18 | 3,983 | 268 | 1,875 | 98 |
| 31 Dec 17 | 2,700 | 162 | 779 | 82 |
Des revenus de qualité: 688658 has high quality earnings.
Augmentation de la marge bénéficiaire: 688658's current net profit margins (4.2%) are lower than last year (7.5%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 688658's earnings have declined by 13.4% per year over the past 5 years.
Accélération de la croissance: 688658's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: 688658 had negative earnings growth (-52.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).
Rendement des fonds propres
ROE élevé: 688658's Return on Equity (4.7%) is considered low.